InvestorsHub Logo
Followers 51
Posts 5357
Boards Moderated 0
Alias Born 09/16/2013

Re: ADVFN_doclee post# 193981

Friday, 10/19/2018 11:59:14 AM

Friday, October 19, 2018 11:59:14 AM

Post# of 711008
ADVFN-DOCLEE,

The into in the phase5 report said the following, not even addressing the other bs throughout and the anonymous authors disclaimers:

In 2016, Northwest Biotherapeutics (OTCQB:NWBO) will have been developing the DCVax dendritic vaccine for exactly 20 years. This bio-failure-in-the-making exhibits all the obvious signs of a looming disaster: clinical trials stretching over decades, half a dozen trial amendments and extensions, lack of reliable results and publications, an utter mess in reporting on them, and most recently, a sudden unexplained halt to patient enrollment in the Phase 3 trial of the company's lead candidate. NWBO has used probably every trick in the book to prevent the inevitable end and announcing the results of its clinical trials, and for a good reason: as long as failure is not announced, the dream can live on and fresh money can be raised by NWBO which then feeds it to NWBO CEO's private companies.

[By the way aren't these positions similar to some on this mb?]



This phase 5 report had very little impact on NWBO's pps....until Neil Woodford's open letter to NWBO (which was filed with the SEC). It was only after Woodford's letter that the phase 5 report dramatically effect the stock price. Linda, imo, took on a more defensive posture toward NW.

Now you can hold the views that
(1) Woodford's letter was not intended to harm NWBO.

(2) Ms. Wolf from Ondra (pushed by Woodford) and the resulting conflict of interest was an innocent error.

(3) Perhaps, one too can conclude, that Woodford's recommendation of Leary ( who had never served on any board, had no biotech experience and no pharma experience other than certain government investigations, had no experience working with companies subjected to stock manipulation, had no experience interacting with investors or helping with corporate fundraising, had not worked with companies on developing business plans or strategies, had never been asked to go on the board of any other company where he has conducted investigations, and did not anticipate playing an ongoing role on NW Bio’s board after the investigation is completed and indicated he would probably resign at that time) to NWBO's board was good for NWBO.

But I think it would be more reasonable for LP to conclude NW was a wolf in sheep clothing.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News